azimilide has been researched along with Disease Models, Animal in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carlsson, L; Kowey, PR; Liu, T; Wu, Y; Yan, GX | 1 |
| Cvetanovic, I; Ke, X; Lin, C; Ranade, V; Somberg, J | 1 |
| Black, SC; Butterfield, JL; Lucchesi, BR | 1 |
| Brooks, RR; Carpenter, JF; Maynard, AE; Miller, KE | 1 |
| Dorian, P; Newman, D; Qi, XQ | 1 |
| Al-Khalidi, H; Brooks, RR; Drexler, AP; Kostreva, DR; Maynard, AE | 1 |
| Clemett, D; Markham, A | 1 |
| Leunissen, JD; Van Opstal, JM; Vos, MA; Wellens, HJ | 1 |
8 other study(ies) available for azimilide and Disease Models, Animal
| Article | Year |
|---|---|
Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Electrocardiography; Hydantoins; Imidazolidines; Male; Phenethylamines; Piperazines; Rabbits; Sulfonamides; Torsades de Pointes | 2005 |
The effect of high extracellular potassium on IKr inhibition by anti-arrhythmic agents.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cells, Cultured; Disease Models, Animal; Electrophysiology; Extracellular Matrix; Female; Hydantoins; Hyperkalemia; Imidazolidines; Oocytes; Phenethylamines; Piperazines; Potassium Channels; Potassium Channels, Voltage-Gated; Probability; Sensitivity and Specificity; Sotalol; Sulfonamides; Xenopus laevis | 2007 |
Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug.
Topics: Animals; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Disease Models, Animal; Dogs; Electric Stimulation; Electrocardiography; Electrophysiology; Heart Rate; Hydantoins; Imidazoles; Imidazolidines; Male; Myocardial Infarction; Piperazines; Piperidines; Tachycardia, Ventricular; Ventricular Fibrillation | 1993 |
Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Chloroform; Constriction; Coronary Vessels; Disease Models, Animal; Dose-Response Relationship, Drug; Guinea Pigs; Heart Rate; Hydantoins; Imidazoles; Imidazolidines; Male; Mice; Ouabain; Piperazines; Propranolol; Rats; Rats, Sprague-Dawley | 1996 |
Azimilide decreases defibrillation voltage requirements and increases spatial organization during ventricular fibrillation.
Topics: Algorithms; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Electric Countershock; Electrodes, Implanted; Electrophysiology; Female; Heart Rate; Hydantoins; Imidazoles; Imidazolidines; Injections, Intravenous; Male; Piperazines; Treatment Outcome; Ventricular Fibrillation | 1999 |
Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit.
Topics: Adrenergic alpha-Agonists; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Female; Hemodynamics; Hydantoins; Imidazoles; Imidazolidines; Male; Methoxamine; Phenethylamines; Piperazines; Procainamide; Quaternary Ammonium Compounds; Rabbits; Sotalol; Sulfonamides | 2000 |
Azimilide.
Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Dogs; Headache; Humans; Hydantoins; Imidazoles; Imidazolidines; Piperazines; Recurrence; Torsades de Pointes | 2000 |
Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of Torsade de Pointes arrhythmias.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Dogs; Heart Block; Hydantoins; Imidazoles; Imidazolidines; Phenethylamines; Piperazines; Sulfonamides; Torsades de Pointes; Ventricular Function | 2001 |